KOCITAF克西他夫三合一 PrEP价格 | 哪里买?

作者:PrEP吧 2020-07-06 浏览:13211
导读: Kocitaf Tablet Dolutegravir (50mg)+Emtricitabine (200mg)+Tenofovir Alafenamide (25mg)克西他夫三合一 治疗和预防HIV / AIDSDolutegravir (多替拉韦钠), Emtricitabine (恩曲他滨)...

KOCITAF克西他夫三合一 PrEP价格 | 哪里买?

Kocitaf Tablet Dolutegravir (50mg)+Emtricitabine (200mg)+Tenofovir Alafenamide (25mg)克西他夫三合一 治疗和预防HIV / AIDS

Dolutegravir (多替拉韦钠), Emtricitabine (恩曲他滨), Tenofovir Alafenamide (替诺福韦艾拉酚胺) 三合一Spegra一天只需服用一片,是一种用于治疗和预防HIV / AIDS的药物,是3种核苷逆转录酶抑制剂(NRTI)的固定剂量组合。这种药物从血液中过滤掉HIV病毒,控制艾滋病。不能治愈AIDS病,但有助于预防艾滋病

DTG/FTC/TAF is comprised of Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg

Mylan's DTG/FTC/TAF will be the first TAF-based fixed-dose combination to be offered to patients in developing countries being treated for HIV -

HERTFORDSHIRE, England and PITTSBURGH, Feb. 20, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced receipt of tentative approval from the U.S. Food and Drug Administration (FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg. The antiretroviral (ARV) will be immediately available in developing countries as a first-line regimen for people being treated for HIV/AIDS.

Mylan is the world's largest producer of HIV/AIDS drugs, and more than 40% of people being treated worldwide for HIV/AIDS depend on a Mylan antiretroviral product.

"The FDA's tentative approval of Mylan's Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets sets a new standard for affordable access for patients in countries hardest hit by HIV, as it's the first time a product combines dolutegravir and tenofovir alafenamide," said Mylan CEO Heather Bresch. "With limited funding, the world needs cost competitive and clinically effective products like this one, and Mylan is proud to work with partners to make it available and help reach the more than 15 million people living with HIV worldwide who still need access to treatment."

Mylan's ARV is a once-daily, fixed-dose combination of Dolutegravir, Emtricitabine and Tenofovir Alafenamide, the individual components that make up ViiV Healthcare's Tivicay® and Gilead's Descovy®. Mylan manufactures these products under licenses from the Medicines Patent Pool and Gilead Sciences, respectively. This is the first tentative approval of Tenofovir Alafenamide and comes just two years after the FDA approval of Descovy®. The combination of these agents is currently included as a "Recommended Initial Regimen for Most People with HIV" in the HIV guidelines of the U.S. Department of Health and Human Services.

"In the past decade, Mylan has committed itself again and again to bringing new therapeutic options to people living with HIV as quickly as possible and to as many people as possible," said Mylan President Rajiv Malik. "We are proud that Mylan has been the first supplier to receive FDA approval for nearly half of the new medicines under PEPFAR since 2009. In the last year alone, we have been the first company to receive approval for three new fixed-dose combination products that use a lower dose of Efavirenz, Dolutegravir, and now Dolutegravir in combination with Tenofovir Alafenamide."

The tablet will be the smallest sized single-tablet regimen available for patients in the developing world. It will be offered in a 90-day package as well as a 30-day one, potentially allowing patients fewer trips to the clinics for a refill.

Mylan's Commitment to the Treatment of HIV/AIDS

For more than a decade, Mylan has been a leader in providing access to quality, dependable and affordable ARVs in more than 100 countries around the world. This includes introducing in 2009 the first generic one-tablet-once-a-day combination for developing countries – only three years after the originator product launched in the U.S. Since that time, Mylan has been the first to market with nearly half of the new products approved under the FDA's PEPFAR program. Mylan was also the first generic drug maker to develop a heat-stable version of a drug critical for second-line regimens, and is the leading supplier of pediatric ARVs, including taste-masked and dispersible formulations. Mylan has also long been a supporter of the patient community through the sponsorship of free community HIV/AIDS testing and clinical research. Learn more about Mylan's work with infectious disease here. Watch this video to learn more about Mylan's commitment to people living with HIV/AIDS.

Kocitaf Tablet 克西他夫三合一

规格:每粒50mg+200mg+25mg,30粒/盒

生产厂家:Mylan

成分:Dolutegravir (50mg), Emtricitabine (200mg), Tenofovir Alafenamide (25mg)

如何使用DOLUTEGRAVIR

按照医生建议的剂量和持续时间服用该药。整体吞下。不要咀嚼,压碎或弄碎它。

如何使用恩曲他滨

按照医生建议的剂量和持续时间服用该药。整体吞下。不要咀嚼,压碎或弄碎它。

如何使用替诺福韦ALAFENAMIDE

按照医生建议的剂量和持续时间服用该药。整体吞下。不要咀嚼,压碎或弄碎它。

DOLUTEGRAVIR如何运作

Dolutegravir是一种抗HIV药物。它可以防止病毒在人细胞中繁殖。这可以阻止病毒产生新病毒并清除感染。

恩曲他滨如何工作

恩曲他滨是一种抗病毒药物。它可以防止病毒在人细胞中繁殖。这可以阻止病毒产生新病毒并清除感染。

TENOFOVIR ALAFENAMIDE如何运作

Tenofovir Alafenamide是一种抗病毒药物。它可以防止病毒在人细胞中繁殖。这可以阻止病毒产生新病毒并清除感染。

关于恩曲他滨

与其他药物结合使用,可用于治疗HIV感染。

随食物一起服用,因为这会增加药物对人体的吸收。

恩曲他滨可能引起头昏眼花或嗜睡。在知道会如何影响自己之前,请勿开车或做任何需要专注的事情。

服用这种药物时,您仍可能会出现感染或与病毒感染有关的其他疾病。

您也可以将HIV或HBV传染给他人。请勿共用可能沾有血液或体液的针头或个人物品。

在治疗期间以及停药后至少六个月,需要定期进行血液检查以监测您的肝功能,乙型肝炎病毒水平和血液中的血细胞。


PrEP预防,PEP阻断,HIV服药组合咨询微信:likeprep100
本文由:PrEP吧整理:http://www.prepba.com/p/1079.html

HIV高危阻断